<DOC>
	<DOCNO>NCT00662636</DOCNO>
	<brief_summary>RATIONALE : Dasatinib lapatinib ditoslylate may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose dasatinib lapatinib ditoslylate give together treat patient advance solid tumor remove surgery .</brief_summary>
	<brief_title>Dasatinib Lapatinib Ditolsylate Treating Patients With Advanced Solid Tumors That Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose dasatinib combine lapatinib . II . To describe toxicity associate treatment combination . III . To assess pharmacokinetic interaction lapatinib dasatinib . IV . To assess effect lapatinib dasatinib combination circulate tumor cell osteoclast precursor activation . V. To study association clinical ( toxicity and/or tumor response activity ) pharmacokinetic parameter , and/or biologic ( pharmacodynamic ) result . VI . To describe response treatment combination . OUTLINE : This multicenter , phase I , dose-escalation study . COHORT I : Patients receive oral dasatinib oral lapatinib ditosylate daily day 1-28 . COHORT II : Patients receive oral dasatinib daily day 1 9-28 oral lapatinib ditosylate daily day 2-28 course 1 . In subsequent course patient receive oral dasatinib oral lapatinib ditosylate daily day 1-28 . In cohort course repeat every 28 day , absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Histologic proof cancer unresectable refractory refuse standard treatment disease Please contact study investigator and/or consult protocol document specific detail laboratory criterion Ability provide inform consent Willingness return Mayo Clinic follow Life expectancy &gt; = 12 week Negative serum pregnancy test do = &lt; 7 day prior registration woman childbearing potential Echocardiogram ejection fraction &gt; 50 % ECOG performance status ( PS ) 02 Able swallow pill whole ( patient feed tube may eligible whole pill take tolerated feed tube ) Willingness provide biologic specimen require protocol Cohort II , ( MTD ) patient Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment Pregnant woman Any follow prior therapy : chemotherapy = &lt; 4 week prior registration ; mitomycin C/nitrosoureas = &lt; 6 week prior registration ; immunotherapy = &lt; 4 week prior registration ; biologic therapy = &lt; 4 week prior registration Patients treat Avastin , Herceptin , Erbitux eligible last treatment &gt; = 4 week ; molecularly target agent ( erlotinib , sunitinib , sorafenib , gefitinib , imatinib ) = &lt; 4 week prior registration ; radiation therapy = &lt; 4 week prior registration ; radiation &gt; 25 % bone marrow CNS metastases stable least 4 week prior registration base imaging , clinical assessment , use steroid Men woman childbearing potential unwilling employ adequate contraception throughout study 4 week follow study Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFDAapproved indication context research investigation ) Current therapy CYP3A4 inhibitor inducer Known standard therapy patient 's disease refractory treatment potentially curative definitely capable extend life expectancy Uncontrolled pleural pericardial effusion grade Uncontrolled angina , congestive heart failure MI within 6 month prior registration Diagnosed congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Subjects potassium magnesium within normal limit correct prior registration New York Heart Association classification III IV Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent ( = &lt; 3 month prior registration ) significant gastrointestinal bleeding Prophylactic use colonystimulating factor study allow Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) G.I condition may interfere drug absorption Ulcerative Colitis , Crohn 's Disease , Short Bowel Syndrome Active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator 's assessment ) Nursing woman Uncontrolled infection Seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>